CXCR7 participates in CXCL12-induced CD34+ cell cycling through b-arrestin-dependent Akt activation

Abstract

In addition to its well-known effect on migration and homing of hematopoietic stem/progenitor cells (HSPCs), CXCL12 chemokine also exhibits a cell cycle and survival-promoting factor for human CD34+ HSPCs. CXCR4 was suggested to be responsible for CXCL12-induced biological effects until the recent discovery of its second receptor, CXCR7. Until now, the participation of CXCR7 in CXCL12-induced HSPC cycling and survival is unknown. We show here that CXCL12 was capable of binding CXCR7 despite its scarce expression at CD34 1 cell surface. Blocking CXCR7 inhibited CXCL12-induced Akt activation as well as the percentage of CD34+ cells in cycle, colony formation, and survival, demonstrating its participationin CXCL12-induced functional effectsin HSPCs. At steady state, CXCR7 and β-arrestin2 co-localized near the plasmamembrane of CD34+ cells. After CXCL12 treatment, β-arrestin2 translocated to the nucleus, and this required both CXCR7 and CXCR4. Silencing β-arrestin expression decreased CXCL12-induced Akt activation in CD34+ cells. Our results demonstrate for the first time the role of CXCR7, complementaryto that played by CXCR4, inthe control of HSPC cycling, survival, and colony formation inducedby CXCL12. We also provide evidence for the involvement of β-arrestins as signaling hubs downstream of both CXCL12 receptors in primary human HSPCs. © 2014 by The American Society of Hematology.